Article Per Year (5 Year)
p-Index From 2019 - 2024
0.444
P-Index
This Author published in this journals
All Journal Narra J Narra X
Acharya, Yogesh
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Physics Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Efficacy of acetazolamide and loop diuretics combinatorial therapy in congestive heart failure: A meta-analysis Duta , Teuku F.; Zulfa , Putri O.; Alina, Meulu; Henira, Najlaika; Tsurayya, Ghina; Fakri, Fajar; Acharya, Yogesh
Narra X Vol. 2 No. 1 (2024): April 2024
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narrax.v2i1.124

Abstract

Acetazolamide, one of the carbonic anhydrase inhibitors, has been known to improve the efficacy of diuretic therapy in patients with in congestion heart failure. The aim this study was to investigate the effectiveness of acetazolamide when combined with loop diuretics in ameliorating diuresis and natriuresis in congestive heart failure using systematic review and meta-analysis. Randomized controlled trials (RCTs) and cohort studies were searched on PubMed, Scopus, and Embase on March 7, 2023, by using combinations of ‘acetazolamide’, ‘heart failure’ and along with their respective synonyms. The protocol had been registered on PROSPERO (CRD42023409864). The studies must investigate the effect of oral acetazolamide as the add-on to loop diuretic therapy to be included. Successful decongestion, natriuresis, and diuresis were set as the primary outcomes. The quality of the included studies was assessed using the Cochrane risk-of-bias tool for RCTs and Newcastle Ottawa Scale for observational studies. We identified 1176 titles in the initial search, and further reduced to five studies (three RCTs and two cohort studies) after in-depth screening. A total of 625 patients were recruited in the included studies published from 2015 to 2022. Results from meta-analysis revealed that acetazolamide and loop diuretics combination therapy ameliorated natriuresis (n=4; standardized means difference (SMD)=0.65; 95%CI: 0.07–1.24; p=0.03) and diuresis (n=2; SMD=0.29; 95%CI: 0.12–0.46; p=0.0009) when compared to loop diuretics alone. Acetazolamide and loop diuretics combinatorial therapy is efficacious in alleviating congestion in heart failure patients.
Acute severe hepatitis of unknown etiology in children: A mini-review Frediansyah, Andri; Sallam, Malik; Yufika, Amanda; Sharun, Khan; Iqhrammullah, Muhammad; Chandran, Deepak; Mamada, Sukamto S.; Sallam, Dina E.; Khader, Yousef; Lemu, Yohannes K.; Yusuf, Fauzi; Kretchy, James-Paul; Abdeen, Ziad; Torres-Roman, J. Smith; Acharya, Yogesh; Bondarenko, Anastasia; Ikram, Aamer; Jamil, Kurnia F.; Kotfis, Katarzyna; Koyanagi, Ai; Smith, Lee; Megawati, Dewi; Rademaker, Marius; Emran, Talha B.; Memish, Ziad A.; Vento, Sandro; Nainu, Firzan; Harapan, Harapan
Narra J Vol. 2 No. 2 (2022): August 2022
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v2i2.83

Abstract

The emergence of acute, severe non hepA–E hepatitis of unknown etiology (ASHUE) has attracted global concern owing to the very young age of the patients and its unknown etiology. Although this condition has been linked to several possible causes, including viral infection, drugs and/or toxin exposure, the exact cause remains unknown; this makes treatment recommendation very difficult. In this review, we summarize recent updates on the clinical manifestations, complemented with laboratory results, case numbers with the global distribution and other epidemiological characteristics, and the possible etiologies. We also provide the proposed actions that could be undertaken to control and prevent further spread of this hepatitis. Since many etiological and pathological aspects of the acute non hepA–E hepatitis remain unclear, further research is needed to minimize the severe impact of this disease.
Co-Authors Abdeen, Ziad Alina, Meulu Andri Frediansyah, Andri Bondarenko, Anastasia Chandran, Deepak Duta , Teuku F. Emran, Talha B. Fakri, Fajar Fauzi Yusuf, Fauzi Firzan Nainu Harapan Harapan Henira, Najlaika Ikram, Aamer Iqhrammullah, Muhammad Khader, Yousef Kotfis, Katarzyna Koyanagi, Ai Kretchy, James-Paul Kurnia F. Jamil Lemu, Yohannes K. Mamada, Sukamto S. Megawati, Dewi Memish, Ziad A. Rademaker, Marius Sallam, Dina E. Sallam, Malik Sharun, Khan Smith, Lee Torres-Roman, J. Smith Tsurayya, Ghina Vento, Sandro Yufika, Amanda Zulfa , Putri O.